Published in J Infect Dis on March 01, 1969
Shiga and Shiga-like toxins. Microbiol Rev (1987) 8.58
The pathogenesis of Shigella diarrhea. I. Enterotoxin production by Shigella dysenteriae I. J Clin Invest (1972) 4.05
Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. Infect Immun (1999) 2.78
Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infect Immun (1986) 2.64
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol (2007) 2.11
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect Immun (1991) 1.47
Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun (2000) 1.44
Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun (1996) 1.38
Dose-response relationships for environmentally mediated infectious disease transmission models. PLoS Comput Biol (2017) 1.37
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun (1996) 1.32
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect Immun (1996) 1.22
Fluid and electrolyte transport in rhesus monkeys challenged intracecally with Shigella flexneri 2a. Infect Immun (1976) 1.16
Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol (2013) 1.13
Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun (2004) 1.07
The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies. Philos Trans R Soc Lond B Biol Sci (2000) 1.06
Lactulose therapy in Shigella carrier state and acute dysentery. Antimicrob Agents Chemother (1975) 1.04
Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery. J Clin Microbiol (1992) 1.01
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect Immun (2001) 1.01
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun (1996) 1.00
Development of an improved animal model of shigellosis in the adult rabbit by colonic infection with Shigella flexneri 2a. Infect Immun (1995) 0.98
Reassessment of the Enteropathogenicity of Mesophilic Aeromonas Species. Front Microbiol (2016) 0.92
Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun (2009) 0.88
Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine (2012) 0.84
Virulence versus resistance. Bull N Y Acad Med (1987) 0.80
IS3 profiling identifies the enterohaemorrhagic Escherichia coli O-island 62 in a distinct enteroaggregative E. coli lineage. Gut Pathog (2011) 0.78
Characterization of intracellular growth regulator icgR by utilizing transcriptomics to identify mediators of pathogenesis in Shigella flexneri. Infect Immun (2013) 0.77
Microscopic examination of stools from nonhuman primates as a way of predicting the presence of Shigella. J Clin Microbiol (1980) 0.75
Low compliance with national guidelines for preventing transmission of group 1 nationally notifiable infectious diseases in Korea. Yonsei Med J (2014) 0.75
EPITHELIAL CELL PENETRATION AS AN ESSENTIAL STEP IN THE PATHOGENESIS OF BACILLARY DYSENTERY. J Bacteriol (1964) 19.60
Involvement of a plasmid in the invasive ability of Shigella flexneri. Infect Immun (1982) 13.55
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science (1984) 7.94
Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun (1983) 6.43
Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect Immun (1981) 6.40
Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis (1974) 6.38
Plasmid-associated enterotoxin production in a strain of Escherichia coli isolated from humans. Infect Immun (1972) 6.21
Detection and characterization of colonization factor of enterotoxigenic Escherichia coli isolated from adults with diarrhea. Infect Immun (1978) 5.71
Protein synthesis in HeLa or Henle 407 cells infected with Shigella dysenteriae 1, Shigella flexneri 2a, or Salmonella typhimurium W118. Infect Immun (1981) 5.39
Typhoid fever: pathogenesis and immunologic control. N Engl J Med (1970) 4.95
Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet (1983) 4.89
Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen. Infect Immun (1980) 4.87
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli. Infect Immun (1983) 4.82
Shigellosis due to Shigella dysenteriae. 1. Relative importance of mucosal invasion versus toxin production in pathogenesis. J Infect Dis (1972) 4.60
Hemagglutination patterns of enterotoxigenic and enteropathogenic Escherichia coli determined with human, bovine, chicken, and guinea pig erythrocytes in the presence and absence of mannose. Infect Immun (1979) 4.60
Experimental bacillary dysentery. An electron microscopic study of the response of the intestinal mucosa to bacterial invasion. Am J Pathol (1965) 4.42
Invasion of HeLa cells by Salmonella typhimurium: a model for study of invasiveness of Salmonella. J Infect Dis (1973) 4.22
Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) (1969) 4.20
Plaque formation by virulent Shigella flexneri. Infect Immun (1985) 4.16
Fecal leukocytes in diarrheal illness. Ann Intern Med (1972) 3.89
Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun (1986) 3.87
Infantile diarrhea produced by heat-stable enterotoxigenic Escherichia coli. N Engl J Med (1976) 3.82
Identification and antigenic characterization of virulence-associated, plasmid-coded proteins of Shigella spp. and enteroinvasive Escherichia coli. Infect Immun (1985) 3.78
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Virulence of Shigella flexneri hybrids expressing Escherichia coli somatic antigens. Infect Immun (1972) 3.33
Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol (1980) 3.31
Inhibition of in vitro protein synthesis by Shigella dysenteriae 1 toxin. Biochem Biophys Res Commun (1976) 3.30
Intracellular spread of Shigella flexneri associated with the kcpA locus and a 140-kilodalton protein. Infect Immun (1989) 3.24
Inactivation of Norwalk virus in drinking water by chlorine. Appl Environ Microbiol (1985) 3.12
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis (2001) 3.08
Patterns of loss of enterotoxigenicity by Escherichia coli isolated from adults with diarrhea: suggestive evidence for an interrelationship with serotype. Infect Immun (1977) 3.04
A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli. J Infect Dis (1985) 2.94
Biological properties of Shigella flexneri 2A toxin and its serological relationship to Shigella dysenteriae 1 toxin. Infect Immun (1977) 2.94
Comparative susceptibility of latin american and united states students to enteric pathogens. N Engl J Med (1976) 2.94
Molecular characterization of plasmids from virulent and spontaneously occurring avirulent colonial variants of Shigella flexneri. Infect Immun (1979) 2.93
Pathogenesis of salmonellosis. Studies of fluid secretion, mucosal invasion, and morphologic reaction in the rabbit ileum. J Clin Invest (1973) 2.78
Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen. Infect Immun (1978) 2.78
Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect (2010) 2.77
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med (1982) 2.71
Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrob Agents Chemother (1976) 2.71
Virulence of three distinct Cryptosporidium parvum isolates for healthy adults. J Infect Dis (1999) 2.65
Role of Escherichia coli colonisation factor antigen in acute diarrhoea. Lancet (1978) 2.65
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med (1970) 2.63
Fluorescent-antibody and histological study of vaccinated and control monkeys challenged with Shigella flexneri. J Bacteriol (1966) 2.60
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Adverse effect of lomotil therapy in shigellosis. JAMA (1973) 2.57
Exerimental acute colitis in the Rhesus monkey following peroral infection with Shigella flexneri. An electron microscope study. Am J Pathol (1968) 2.53
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Virulence factors of enterotoxigenic Escherichia coli. J Infect Dis (1977) 2.45
Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect Control (1981) 2.43
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
The isolation and characterization of a Norwalk virus-specific cDNA. J Clin Invest (1991) 2.42
Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev (1966) 2.42
Plasmid-mediated invasiveness of "Shigella-like" Escherichia coli. Ann Microbiol (Paris) (1982) 2.38
Pathogenicity of enteroadherent Escherichia coli in adult volunteers. J Infect Dis (1986) 2.32
Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect (2008) 2.30
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis (1972) 2.29
Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med (1982) 2.27
Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol (1966) 2.23
Diarrhea caused by Shigella, rotavirus, and Giardia in day-care centers: prospective study. J Pediatr (1981) 2.21
Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother (1983) 2.20
Invasive Escherichia coli. J Infect Dis (1978) 2.19
Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA (1980) 2.16
Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun (1981) 2.15
Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunization with inactivated virus. Nature (1968) 2.10